1. 主頁
  2. 胡子祺

胡子祺

胡子祺, 羅旭龢基金教授(公共衞生學), 教授, 流行病和生物統計學, BS, PhD, FFPH, phone: 3917 6709, email: joewu@hku.hk

羅旭龢基金教授(公共衞生學)

教授

流行病和生物統計學

  • BS, PhD, FFPH
phone 3917 6709
email joewu@hku.hk
scholarsHub http://hub.hku.hk/cris/rp/rp00517
pub med PubMed
個人簡介
胡子祺教授現任公共衞生學院教授，主要研究領域為疾病數學建模與統計分析。其研究旨在開發具實用價值的疾病防控分析模型與策略，研究項目涵蓋新型冠狀病毒病、季節性及流感大流行、手足口病、人類乳突病毒（HPV）、中東呼吸綜合症（MERS）、黃熱病、子宮頸癌、大腸癌及乳腺癌等。胡教授在麻省理工學院獲得運籌學博士學位及化學工程學士學位。

胡教授同時擔任「醫衞大數據深析實驗室」（D24H）董事總經理，領導團隊研發人工智能技術與工具，致力於全球及個人健康保護，重點聚焦於臨床自然語言處理、疫情即時趨勢預測及疫苗猶豫等領域。

作為香港大學首個「大規模開放在線課程」(MOOC)《傳染病學》的創辦總監，胡教授主持的該課程自2014年首次推出以來已吸引逾五萬名學員修讀。此外，他亦擔任兩個「裘槎暑期課程」（疫苗學與疫苗猶豫）的學術總監。

胡教授現為國際期刊《Epidemics》的聯合主編，並擔任《PLOS Computational Biology》與《PLOS Neglected Tropical Diseases》副編輯。他獲英國公共衞生學院授予院士榮銜（Fellow of the UK Faculty of Public Health），並於2018至2023年間擔任世界衞生組織「免疫接種與疫苗相關實施研究諮詢委員會」（IVIR-AC）委員。
發表的部分文章
  1. Wu JT, Leung K, Bushman M, Kishore N, Niehus R, M de Salazar P, Cowling BJ, Lipsitch M, Leung GM. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nature Medicine. 2020.
  2. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet; 395(10225): 689–697. doi:10.1016/S0140-6736(20)30260-9 (2020).
  3. Wang L, Wu JT. Characterizing the dynamics underlying global spread of epidemics. Nature Communications, 9(1):218 (2018).
  4. Leung K, Lipsitch M, Yuen KY, Wu JT. Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study. The Lancet Infectious Diseases, 17(3): 339-347 (2017).
  5. Wu JT, Peak C, Leung GM & Lipsitch M. Fractional Dosing of Yellow Fever Vaccine to Extend Supply: A Modeling Study. The Lancet. doi: 10.1016/S0140-6736(16)31838-4 (2016).
  6. Wu JT, Jit, M, Zheng, Y, Leung, K, Xing, W, Yang, J, Liao, Q, Cowling, BJ, Yang, B, Lau, EH, Takahashi, S, Farrar, JJ, Grenfell, BT, Leung, GM & Yu, H. Routine Pediatric Enterovirus 71 Vaccination in China: a Cost-Effectiveness Analysis. PLoS Medicine 13, e1001975, doi:10.1371/journal.pmed.1001975 (2016).
  7. Wu JT, Ho, A, Ma, ES, Lee, CK, Chu, DK, Ho, PL, Hung, IF, Ho, LM, Lin, CK, Tsang, T, Lo, SV, Lau, YL, Leung, GM, Cowling, BJ & Peiris, JS. Estimating Infection Attack Rates and Severity in Real Time during an Influenza Pandemic: Analysis of Serial Cross-Sectional Serologic Surveillance Data. PLoS Medicine 8, e1001103, doi:10.1371/journal.pmed.1001103 (2011).
  8. Wu JT, Lee, CK, Cowling, BJ & Yuen, KY. Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic. Proceedings of the National Academy of Sciences of the United States of America 107, 3269-3274, doi:10.1073/pnas.0911596107 (2010).
  9. Wu JT, Leung, GM, Lipsitch, M, Cooper, BS & Riley, S. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Medicine 6, e1000085, doi:10.1371/journal.pmed.1000085 (2009).
  10. Wu JT, Riley, S, Fraser, C & Leung, GM. Reducing the impact of the next influenza pandemic using household-based public health interventions. PLoS Medicine 3, e361, doi:10.1371/journal.pmed.0030361 (2006).
返回